| Target | HER-2/neu |
|---|
| Application | ELISA, FC |
|---|
| Clonality | Monoclonal |
|---|
| Conjugate | Biotin |
|---|
| Isotype | Human IgG1κ |
|---|
| Immunogen | Human epidermoid carcinoma cells (A431) over-expressing EGFR. |
|---|
| Species Reactivity | Human |
|---|
| Formulation | This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. |
|---|
| Research Area | Cancer, Immunology |
|---|
| Description/Background | Trastuzumab is a monoclonal antibody targeting HER2, a 185 kDa transmembrane glycoprotein that contains an extracellular domain and intracellular tyrosine kinase activity. When it is functioning normally, the HER2 pathway supports cell growth and division. On the other hand, the over expression of HER2 propels cell growth beyond its typical range. This overexpression is associated with some cancers, namely breast and stomach, in which the HER2 protein can be expressed up to 100 times more than in typical cells. Trastuzumab induces an immune-mediated response that triggers the internalization and downregulation of HER2 making it an excellent target for immunotherapy. Several clinical studies are under way which show that anti-HER-2/neu antibodies inhibit the growth and proliferation of these tumor cells In vitro as well as In vivo. |
|---|
| Storage Temperature | This biotinylated antibody is stable when stored at 2-8°C. Do not freeze. |
|---|
| Protocols | ELISA, FC |
|---|
| Clone Number | 4D5-8 |
|---|
| Concentration | 0.5 mg/ml |
|---|
| Regulatory Statement | For Research Use Only. Not for use in diagnostic procedures. |
|---|
